Packaging
Valois Pharma announces resounding success for the 3rd Chinese Nasal and Pulmonary Drug Delivery Symposium
Friday 28. November 2008 - Valois Pharma, world leader in nasal and pulmonary drug delivery devices, co-organized with sister company Pfeiffer, through Aptar Pharma Asia, the Third International Symposium on Nasal and Pulmonary Drug Delivery, held in Suzhou, China, on November 11th and 12th.
The first such Chinese scientific conference tailored specifically for this sector was held in 2004. Now a mature event, this years symposium saw 118 delegates attend, with major participation by scientists and technical experts from Chinas pharmaceutical industry, as well as representatives from universities and centers of research across China.
Delegates attended 20 presentations given by highly respected Chinese scientists over the two days. Speakers included the SFDA (State Food and Drug Administration), as well as globally-recognized international experts such as Prof. Richard Dalby, from Maryland University in the U.S.
A major scientific contribution from Valois Pharma
The program was structured into three sessions: Pulmonary Drug Delivery (for treating asthma and chronic bronchitis) and phase out of CFC propellants replaced by more environmentally-friendly compounds; Dry Powder Inhaler delivery technology; Pulmonary and Nasal Drug Delivery.
Three experts from Valois Pharma gave lectures:
Guillaume Brouet, Director of Pulmonary Business Development: “Worldwide market for respiratory drugs” and “DPI delivery device technology”;
Dr Gerallt Williams, Director Laboratories Services: “Recent advances in analytical testing of pharmaceutical aerosols”;
Hervé Pacaud, Director Business Development Pumps: “Worldwide nasal market: update and trends”.
A significant investment by Valois Pharma in China
The significant industrial investment made by Valois Pharma in China through Aptar Pharma Asia contributed to the success of the symposium. Aptar Pharma Asia was established in Suzhou in 1996, and today there are more than 170 Aptar Pharma Asia employees at the 4,500 sqm factory in China, manufacturing and selling, among others, Valois Pharma brand metering valves for pressurized inhalers.
Valois Pharma is a recognized market leader in China and continues to expand its activity, leveraging an indepth network of local partners to forge strong links with a wide range of players in China, including those in research, industry, academia and regulating bodies.
Jointly organizing this 3rd symposium in China is part of Valois Pharmas global strategy to promote and develop nasal and pulmonary drug delivery technology and expertise internationally.